Identifying the Intracellular Function of APOL1.
作者信息
Bruggeman Leslie A, O'Toole John F, Sedor John R
机构信息
Department of Medicine, MetroHealth Medical Center and
Department of Medicine, MetroHealth Medical Center and.
出版信息
J Am Soc Nephrol. 2017 Apr;28(4):1008-1011. doi: 10.1681/ASN.2016111262. Epub 2017 Feb 14.
Abstract
摘要
相似文献
1
Identifying the Intracellular Function of APOL1.确定载脂蛋白L1（APOL1）的细胞内功能。
J Am Soc Nephrol. 2017 Apr;28(4):1008-1011. doi: 10.1681/ASN.2016111262. Epub 2017 Feb 14.
2
Genetics: APOL1 risk variants drive kidney disease in mice.
Nat Rev Nephrol. 2017 May;13(5):259. doi: 10.1038/nrneph.2017.35. Epub 2017 Mar 6.
3
Arrest of the true culprit and acquittal of the innocent? Genetic revelations charge APOL1 variants with kidney disease susceptibility.逮捕真凶并宣告无辜者无罪？基因揭示表明APOL1变异体与肾脏疾病易感性有关。
Int Urol Nephrol. 2010 Dec;42(4):1131-4. doi: 10.1007/s11255-010-9863-z. Epub 2010 Nov 16.
4
APOL1-G1 in Nephrocytes Induces Hypertrophy and Accelerates Cell Death.肾细胞中的载脂蛋白L1 G1型诱导肥大并加速细胞死亡。
J Am Soc Nephrol. 2017 Apr;28(4):1106-1116. doi: 10.1681/ASN.2016050550. Epub 2016 Nov 18.
5
APOL1 Kidney Disease Risk Variants: An Evolving Landscape.载脂蛋白L1肾病风险变异体：不断演变的格局
Semin Nephrol. 2015 May;35(3):222-36. doi: 10.1016/j.semnephrol.2015.04.008.
6
APOL1 nephropathy: from gene to mechanisms of kidney injury.载脂蛋白L1肾病：从基因到肾损伤机制
Nephrol Dial Transplant. 2016 Mar;31(3):349-58. doi: 10.1093/ndt/gfu391. Epub 2015 Jan 5.
7
APOL1: a case in point for replacing race with genetics.APOL1：用遗传学取代种族的一个典型例子。
Kidney Int. 2017 Apr;91(4):768-770. doi: 10.1016/j.kint.2017.02.002.
8
"Biomarking" the transition from genetic risk to kidney disease.从遗传风险到肾脏疾病的转变的生物标志物。
Kidney Int. 2018 Jun;93(6):1270-1272. doi: 10.1016/j.kint.2018.03.005.
9
Biogenesis and cytotoxicity of APOL1 renal risk variant proteins in hepatocytes and hepatoma cells.载脂蛋白L1（APOL1）肾脏风险变异蛋白在肝细胞和肝癌细胞中的生物合成及细胞毒性
J Lipid Res. 2015 Aug;56(8):1583-93. doi: 10.1194/jlr.M059733. Epub 2015 Jun 18.
10
APOL1 and blood pressure changes in young adults.APOL1 与年轻人的血压变化。
Kidney Int. 2017 Oct;92(4):793-795. doi: 10.1016/j.kint.2017.05.030.
引用本文的文献
1
HIF-2α/LINC02609/APOL1-mediated lipid storage promotes endoplasmic reticulum homeostasis and regulates tumor progression in clear-cell renal cell carcinoma.缺氧诱导因子 2α/LINC02609/APOL1 介导的脂质储存促进内质网稳态并调节肾透明细胞癌中的肿瘤进展。
J Exp Clin Cancer Res. 2024 Jan 23;43(1):29. doi: 10.1186/s13046-023-02940-6.
2
Molecular Dynamic Simulation Reveals Structure Differences in Variants and Implication in Pathogenesis of Chronic Kidney Disease.分子动力学模拟揭示了慢性肾病发病机制中变异体的结构差异及其意义。
Genes (Basel). 2022 Aug 16;13(8):1460. doi: 10.3390/genes13081460.
3
The evolving story of apolipoprotein L1 nephropathy: the end of the beginning.载脂蛋白 L1 肾病的演变故事：开端的结束。
Nat Rev Nephrol. 2022 May;18(5):307-320. doi: 10.1038/s41581-022-00538-3. Epub 2022 Feb 25.
4
Endoplasmic reticulum-translocation is essential for APOL1 cellular toxicity.内质网转位对于载脂蛋白L1（APOL1）的细胞毒性至关重要。
iScience. 2021 Dec 31;25(1):103717. doi: 10.1016/j.isci.2021.103717. eCollection 2022 Jan 21.
5
Podocyte density is reduced in kidney allografts with high-risk APOL1 genotypes at transplantation.移植时具有高风险APOL1基因型的肾移植受者中足细胞密度降低。
Clin Transplant. 2021 Apr;35(4):e14234. doi: 10.1111/ctr.14234. Epub 2021 Feb 10.
6
APOL1 risk variants and the development of HIV-associated nephropathy.APOL1 风险变异体与 HIV 相关肾病的发生。
FEBS J. 2021 Oct;288(19):5586-5597. doi: 10.1111/febs.15677. Epub 2020 Dec 31.
7
Phenome-wide association analysis suggests the APOL1 linked disease spectrum primarily drives kidney-specific pathways.全表型组关联分析表明，载脂蛋白L1（APOL1）相关疾病谱主要驱动肾脏特异性通路。
Kidney Int. 2020 May;97(5):1032-1041. doi: 10.1016/j.kint.2020.01.027. Epub 2020 Feb 17.
8
modifies -induced kidney disease risk.改变 - 诱导的肾脏疾病风险。
Proc Natl Acad Sci U S A. 2018 Mar 27;115(13):3446-3451. doi: 10.1073/pnas.1716113115. Epub 2018 Mar 12.
9
Apolipoprotein L1 confers pH-switchable ion permeability to phospholipid vesicles.载脂蛋白L1赋予磷脂囊泡pH值可切换的离子通透性。
J Biol Chem. 2017 Nov 3;292(44):18344-18353. doi: 10.1074/jbc.M117.813444. Epub 2017 Sep 15.
本文引用的文献
1
APOL1-Mediated Cell Injury Involves Disruption of Conserved Trafficking Processes.APOL1介导的细胞损伤涉及保守运输过程的破坏。
J Am Soc Nephrol. 2017 Apr;28(4):1117-1130. doi: 10.1681/ASN.2016050546. Epub 2016 Nov 18.
2
APOL1-G1 in Nephrocytes Induces Hypertrophy and Accelerates Cell Death.肾细胞中的载脂蛋白L1 G1型诱导肥大并加速细胞死亡。
J Am Soc Nephrol. 2017 Apr;28(4):1106-1116. doi: 10.1681/ASN.2016050550. Epub 2016 Nov 18.
3
Renal-Risk Variants Induce Mitochondrial Dysfunction.肾脏风险变异体导致线粒体功能障碍。
J Am Soc Nephrol. 2017 Apr;28(4):1093-1105. doi: 10.1681/ASN.2016050567. Epub 2016 Nov 7.
4
From man to fish: What can Zebrafish tell us about ApoL1 nephropathy?从人类到鱼类：斑马鱼能告诉我们关于载脂蛋白L1肾病的哪些信息？
Clin Nephrol. 2016;86 (2016)(13):114-118. doi: 10.5414/CNP86S116.
5
APOL1-G0 or APOL1-G2 Transgenic Models Develop Preeclampsia but Not Kidney Disease.APOL1-G0或APOL1-G2转基因模型会发展为子痫前期，但不会发展为肾脏疾病。
J Am Soc Nephrol. 2016 Dec;27(12):3600-3610. doi: 10.1681/ASN.2015111220. Epub 2016 Mar 29.
6
Plasma Levels of Risk-Variant APOL1 Do Not Associate with Renal Disease in a Population-Based Cohort.在一个基于人群的队列中，风险变异型载脂蛋白L1（APOL1）的血浆水平与肾脏疾病无关。
J Am Soc Nephrol. 2016 Oct;27(10):3204-3219. doi: 10.1681/ASN.2015101121. Epub 2016 Mar 22.
7
APOL1 kidney disease risk variants cause cytotoxicity by depleting cellular potassium and inducing stress-activated protein kinases.APOL1肾病风险变异体通过消耗细胞内钾离子和诱导应激激活蛋白激酶而导致细胞毒性。
Proc Natl Acad Sci U S A. 2016 Jan 26;113(4):830-7. doi: 10.1073/pnas.1522913113. Epub 2015 Dec 23.
8
Trypanosome Lytic Factor-1 Initiates Oxidation-stimulated Osmotic Lysis of Trypanosoma brucei brucei.锥虫溶解因子-1引发氧化刺激的布氏布氏锥虫渗透性裂解。
J Biol Chem. 2016 Feb 5;291(6):3063-75. doi: 10.1074/jbc.M115.680371. Epub 2015 Dec 8.
9
Coupling of lysosomal and mitochondrial membrane permeabilization in trypanolysis by APOL1.载脂蛋白L1（APOL1）介导的锥虫溶解过程中溶酶体与线粒体膜通透性的偶联
Nat Commun. 2015 Aug 26;6:8078. doi: 10.1038/ncomms9078.
10
APOL1 toxin, innate immunity, and kidney injury.载脂蛋白L1毒素、固有免疫与肾损伤。
Kidney Int. 2015 Jul;88(1):28-34. doi: 10.1038/ki.2015.109. Epub 2015 Apr 8.
Zotero 插件